Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

Journal: Journal of Clinical Investigation

Published: 2018-08-31

DOI: 10.1172/jci96804

Affiliations: 19

Authors: 21

Go to article
Institutions FC
Department of Biochemistry and Molecular Biology, KU, South Korea 0.12
Department of Biomedical Sciences, KU, South Korea 0.12
School of Korean Medicine, PNU, South Korea 0.10
NIH NCI Experimental Laboratory of Pathology (EPL), United States of America (USA) 0.10
Translational Research Institute for Incurable Diseases, KUMC, South Korea 0.10
Department of Pathology, JHU, United States of America (USA) 0.07
College of Medicine (YUCM), Yonsei University, South Korea 0.05
Seoul National University Hospital (SNUH), South Korea 0.05
Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, United States of America (USA) 0.05
International St. Mary's Hospital, CKU, South Korea 0.05
NIH NCI Radiation Oncology Branch, United States of America (USA) 0.05
Gangnam Severance Hospital, Yonsei University, South Korea 0.05
Research Institute, NCC, South Korea 0.05
Johns Hopkins University School of Medicine (JHUSOM), JHU, United States of America (USA) 0.03
Medical Scientist Training/MD-PhD Program, JHU, United States of America (USA) 0.02
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA) 0.01
Department of Gynecology and Obstetrics, JHU, United States of America (USA) 0.01
W. Harry Feinstone Department of Molecular Microbiology and Immunology, JHU, United States of America (USA) 0.01

Return